David Roman

Q: What is David Roman's success rate?

David Roman currently has a success rate of 91.20605777282391.

Q: What is the average return of David Roman's calls?

Their stock ratings have generated an average return of 14.608149949738998.

Goldman Sachs | Healthcare

David Roman is an analyst from Goldman Sachs specializing in the Healthcare sector. Ranked #1091 out of 4631 analysts, they have issued 40 stock ratings with a success rate of 91.21% and an average return of 14.61%.

David Roman has a well-established track record, with 40 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 91.21% and an average return of 14.61%, underscoring their expertise and ability to identify winning opportunities for investors.

#1091

Out of 4631

Total Ratings

+91.21%

Success Rate

+14.61%

Average Return

Recent Ratings Analysis

BSX

Buy

Apr 23, 2026

Target

$84.00

Current

$64.87

Performance

—

David Roman rated BSX as Buy on Apr 23, 2026, setting a price target of 84. Shares have remained stable near 64.87, leaving the 84 target still in play.

BDX

Hold

Apr 10, 2026

Target

$167.00

Current

$155.65

Performance

0.93%

On Apr 10, 2026, BDX was given a Neutral rating by David Roman, with a target price of 167. Market indecision, reflected in sideways trading near 155.65, supported the cautious call.

ABT

Buy

Apr 09, 2026

Target

$121.00

Current

$91.74

Performance

-10.69%

ABT received a Buy rating from David Roman on Apr 09, 2026, aiming for 121. The rating hasn’t played out as hoped, with the stock trading 10.69% below expectations.

BBNX

Buy

Apr 09, 2026

Target

$20.00

Current

$12.20

Performance

26.69%

On Apr 09, 2026, David Roman published a Buy outlook on BBNX, with a target of 20. Shares gained 26.69%, underscoring the accuracy of the bullish outlook toward 20.

CARL

Buy

Apr 09, 2026

Target

$17.00

Current

$10.62

Performance

9.26%

David Roman on Apr 09, 2026 assigned CARL a Buy rating, with a price target of 17. The Buy call aligned well with market performance, producing a gain of 9.26%.

DOCS

Hold

Apr 09, 2026

Target

$28.00

Current

$24.26

Performance

14.65%

On Apr 09, 2026, David Roman reaffirmed DOCS with a Neutral rating, targeting 28. Market strength beyond 24.26 went further than the conservative outlook suggested.

GEHC

Buy

Apr 09, 2026

Target

$81.00

Current

$71.38

Performance

-2.10%

GEHC was rated Buy by David Roman on Apr 09, 2026, with a price objective of 81. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

IRTC

Hold

Apr 09, 2026

Target

$147.00

Current

$121.95

Performance

3.21%

On Apr 09, 2026, David Roman initiated coverage on IRTC with a Neutral rating and target of 147. The stock’s lack of movement around 121.95 aligned with a cautious approach.

ISRG

Buy

Apr 09, 2026

Target

$609.00

Current

$483.62

Performance

6.30%

David Roman issued a Buy recommendation for ISRG on Apr 09, 2026, price target set at 609. Investors following the Buy call captured upside momentum, with shares now at 483.62.

KMTS

Hold

Apr 09, 2026

Target

$17.00

Current

$23.81

Performance

23.69%

On Apr 09, 2026, KMTS was evaluated by David Roman, who gave a Neutral rating and target of 17. Investors who stayed in despite the Hold saw upside of 23.69%.

OMDA

Buy

Apr 09, 2026

Target

$23.00

Current

$14.61

Performance

21.95%

David Roman rated OMDA as Buy on Apr 09, 2026, setting a price target of 23. The call has proven timely, with shares rising 21.95% toward the price target of 23.

PODD

Buy

Apr 09, 2026

Target

$277.00

Current

$193.62

Performance

-2.91%

On Apr 09, 2026, PODD was given a Buy rating by David Roman, with a target price of 277. The stock traded sideways with a -2.91% move, keeping the bullish thesis unresolved.

SYK

Hold

Apr 09, 2026

Target

$357.00

Current

$329.35

Performance

-2.89%

SYK received a Neutral rating from David Roman on Apr 09, 2026, aiming for 357. Shares remained flat at 329.35, aligning with the neutral rating.

TNDM

Hold

Apr 09, 2026

Target

$25.00

Current

$20.78

Performance

5.59%

On Apr 09, 2026, David Roman published a Neutral outlook on TNDM, with a target of 25. The Hold call missed some of the bullish momentum as shares advanced toward 25.

BAX

Hold

Feb 17, 2026

Target

$21.00

Current

$18.31

Performance

-11.72%

David Roman on Feb 17, 2026 assigned BAX a Neutral rating, with a price target of 21. The call successfully avoided chasing as shares lost 11.72%.

EW

Buy

Feb 11, 2026

Target

$108.00

Current

$81.53

Performance

2.77%

On Feb 11, 2026, David Roman reaffirmed EW with a Buy rating, targeting 108. Market indecision has kept the 108 target in a holding pattern.

MDLN

Buy

Jan 12, 2026

Target

$49.00

Current

$47.16

Performance

10.39%

MDLN was rated Buy by David Roman on Jan 12, 2026, with a price objective of 49. A bullish response from the market helped close the gap of 1.84 to the target.

HQY

Sell

Jan 09, 2026

Target

$89.00

Current

$82.88

Performance

-11.97%

On Jan 09, 2026, David Roman initiated coverage on HQY with a Sell rating and target of 89. Shares gained despite the bearish call, moving higher from 82.88.

COO

Sell

Dec 08, 2025

Target

$71.00

Current

$66.92

Performance

-14.25%

David Roman issued a Sell recommendation for COO on Dec 08, 2025, price target set at 71. The Sell call exposed risks of betting against momentum, as the stock rallied -14.25%.

MDT

Hold

Nov 19, 2025

Target

$111.00

Current

$83.22

Performance

-17.06%

On Nov 19, 2025, MDT was evaluated by David Roman, who gave a Neutral rating and target of 111. The Hold call avoided chasing into subsequent weakness of 17.06%.

GKOS

Buy

Oct 01, 2025

Target

$103.00

Current

$121.65

Performance

46.23%

David Roman rated GKOS as Buy on Oct 01, 2025, setting a price target of 103. The call has proven timely, with shares rising 46.23% toward the price target of 103.

BLCO

Hold

Oct 01, 2025

Target

$16.00

Current

$16.05

Performance

9.41%

On Oct 01, 2025, BLCO was given a Neutral rating by David Roman, with a target price of 16. The stock rallied from 16.05 to 16.05 after the Hold rating, surprising to the upside.

SI

Buy

Aug 25, 2025

Target

$20.00

Current

$13.69

Performance

-8.85%

SI received a Buy rating from David Roman on Aug 25, 2025, aiming for 20. The rating hasn’t played out as hoped, with the stock trading 8.85% below expectations.

ZBH

Hold

May 06, 2025

Target

$104.00

Current

$93.04

Performance

0.83%

On May 06, 2025, David Roman published a Neutral outlook on ZBH, with a target of 104. Sideways action left the Hold view intact, with no major move since 93.04.

TDOC

Buy

Mar 03, 2025

Target

$13.00

Current

$5.92

Performance

-37.22%

David Roman on Mar 03, 2025 assigned TDOC a Buy rating, with a price target of 13. The call has struggled to gain traction, with shares losing 37.22%.

LIVN

Buy

Mar 03, 2025

Target

$55.00

Current

$65.18

Performance

56.23%

On Mar 03, 2025, David Roman reaffirmed LIVN with a Buy rating, targeting 55. The recommendation was supported by strong follow-through as the stock rose from 65.18 to 65.18.

SOLV

Sell

Mar 03, 2025

Target

$71.00

Current

$69.11

Performance

-13.78%

SOLV was rated Sell by David Roman on Mar 03, 2025, with a price objective of 71. The Sell stance proved too pessimistic given the -13.78% climb.

Frequency Asked Questions

Who is David Roman?

David Roman is an analyst from Goldman Sachs specializing in the Healthcare sector.

What is David Roman's success rate?

David Roman currently has a success rate of +91.21%.

How many ratings has David Roman issued?

David Roman has issued 40 stock ratings so far.

What is the average return of David Roman's calls?

Their stock ratings have generated an average return of +14.61%.

What is David Roman's ranking?

David Roman is ranked #1091 out of 4631 analysts.

What types of ratings does David Roman give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow David Roman?

You can follow David Roman by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by David Roman?

Their latest rating was a Buy on BSX issued on 2026-04-23.